Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial

Antifibrotic and molecular aspects of rifaximin in alcoholic liver disease: study protocol for a randomized controlled trial

Abstract Background Alcoholic liver disease is the leading cause of cirrhosis worldwide. Due to an increase in alcohol overuse, alcoholic liver disease has become an increased burden on health care systems. Abstinence from alcohol remains the cornerstone of alcoholic liver disease treatment; however...

Full description

Bibliographic Details
Main Authors: Bjørn Stæhr Madsen, Jonel Trebicka, Maja Thiele, Mads Israelsen, Manimozhiyan Arumugan, Troels Havelund, Aleksander Krag
Format: Article
Language:English
Published: BMC 2018-02-01
Series:Trials
Subjects:
Liver fibrosis
Alcoholic liver disease
Gut microbiota
Rifaximin
Online Access:http://link.springer.com/article/10.1186/s13063-018-2523-9

Internet

http://link.springer.com/article/10.1186/s13063-018-2523-9

Similar Items